CR20190389A - Proteínas de fusión del factor ix y procedimientos de preparación y utilización de las mismas - Google Patents

Proteínas de fusión del factor ix y procedimientos de preparación y utilización de las mismas

Info

Publication number
CR20190389A
CR20190389A CR20190389A CR20190389A CR20190389A CR 20190389 A CR20190389 A CR 20190389A CR 20190389 A CR20190389 A CR 20190389A CR 20190389 A CR20190389 A CR 20190389A CR 20190389 A CR20190389 A CR 20190389A
Authority
CR
Costa Rica
Prior art keywords
fix
fusion proteins
factor
making
methods
Prior art date
Application number
CR20190389A
Other languages
English (en)
Inventor
Der Flier Arjan Van
Zhiqian Liu
Tongyao Liu
Robert T Peters
Ayman Ismail
John Kulman
Ekta Seth Chhabra
David R Light
Original Assignee
Bioverativ Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioverativ Therapeutics Inc filed Critical Bioverativ Therapeutics Inc
Publication of CR20190389A publication Critical patent/CR20190389A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
CR20190389A 2017-01-31 2018-01-31 Proteínas de fusión del factor ix y procedimientos de preparación y utilización de las mismas CR20190389A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762452826P 2017-01-31 2017-01-31
PCT/US2018/016277 WO2018144623A1 (en) 2017-01-31 2018-01-31 Factor ix fusion proteins and methods of making and using same

Publications (1)

Publication Number Publication Date
CR20190389A true CR20190389A (es) 2019-11-26

Family

ID=61193175

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20190389A CR20190389A (es) 2017-01-31 2018-01-31 Proteínas de fusión del factor ix y procedimientos de preparación y utilización de las mismas

Country Status (19)

Country Link
US (1) US20210238259A1 (es)
EP (1) EP3576762A1 (es)
JP (1) JP2020505424A (es)
KR (1) KR20190112763A (es)
CN (1) CN110831613A (es)
AR (1) AR110871A1 (es)
AU (1) AU2018215092A1 (es)
BR (1) BR112019015569A2 (es)
CA (1) CA3051862A1 (es)
CL (1) CL2019002155A1 (es)
CR (1) CR20190389A (es)
EA (1) EA201991768A1 (es)
IL (1) IL268234A (es)
MA (1) MA47416A (es)
MX (1) MX2019009063A (es)
PH (1) PH12019501765A1 (es)
SG (1) SG11201906788XA (es)
TW (1) TW201831521A (es)
WO (1) WO2018144623A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112175088B (zh) * 2019-07-02 2023-03-28 江苏晟斯生物制药有限公司 改进的fix融合蛋白、缀合物及其应用
CN113817759B (zh) * 2020-07-10 2023-06-02 南京吉迈生物技术有限公司 修饰的因子ix、组合物、方法及其在基因治疗中的应用

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4770999A (en) 1985-04-22 1988-09-13 Genetics Institute, Inc. High yield production of active Factor IX
EP0832981A1 (en) 1987-02-17 1998-04-01 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
AU648020B2 (en) 1989-02-21 1994-04-14 Washington University Modified forms of reproductive hormones
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
EP0575545B1 (en) 1991-03-15 2003-05-21 Amgen Inc. Pegylation of polypeptides
US5846951A (en) 1991-06-06 1998-12-08 The School Of Pharmacy, University Of London Pharmaceutical compositions
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
ATE236987T1 (de) 1992-11-13 2003-04-15 Idec Pharma Corp Konsensus-kozak-sequenzen zur säugetier- exprimierung
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
EP0981637B1 (en) 1997-03-14 2005-05-25 Biogen Idec Inc. Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
CA2405709A1 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
AU2002226028A1 (en) 2000-11-14 2002-05-27 Board Of Regents, Unversity Of Texas Systems Mutant human factor ix with an increased resistance to inhibition by heparin
MXPA04001982A (es) 2001-09-04 2004-06-07 Merck Patent Gmbh Factor ix modificado.
CA2471363C (en) 2001-12-21 2014-02-11 Human Genome Sciences, Inc. Albumin fusion proteins
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
KR101271635B1 (ko) 2001-12-21 2013-06-12 휴먼 게놈 사이언시즈, 인코포레이티드 알부민 융합 단백질
EP1824988B1 (en) 2004-11-12 2017-04-19 Bayer HealthCare LLC Site-directed modification of fviii
JP2009504157A (ja) 2005-08-12 2009-02-05 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド アルブミン融合タンパク質
US8048848B2 (en) 2006-02-03 2011-11-01 Prolor Biotech Ltd. Long-acting interferons and derivatives thereof and methods thereof
WO2007149406A2 (en) 2006-06-19 2007-12-27 Nautilus Technology Llc Modified coagulation factor ix polypeptides and use thereof for treatment
BRPI0716744A2 (pt) 2006-09-14 2016-10-04 Human Genome Sciences Inc proteínas de fusão de albumina
US7700734B2 (en) 2007-01-09 2010-04-20 Shu-Wha Lin Recombinant human factor IX and use thereof
CN101970678B (zh) 2007-06-21 2014-08-20 慕尼黑科技大学 具有增加的体内和/或体外稳定性的生物学活性蛋白
CA2702363A1 (en) 2007-10-15 2009-04-23 The University Of North Carolina At Chapel Hill Human factor ix variants with an extended half life
AU2009244633A1 (en) 2008-04-16 2009-11-12 Bayer Healthcare Llc Modified Factor IX polypeptides and uses thereof
KR20110015551A (ko) 2008-04-16 2011-02-16 바이엘 헬스케어 엘엘씨 제ｉｘ인자의 부위-지정 변형
AR071478A1 (es) 2008-04-17 2010-06-23 Baxter Healthcare Sa Peptidos de bajo peso molecular con actividad procoagulante para el tratamiento de pacientes con deficiencia de factor v (fv), fvii, fviii, fx y/o fxi
EP2268807A2 (en) 2008-04-21 2011-01-05 Novo Nordisk A/S Hyperglycosylated human coagulation factor ix
CN102348715B (zh) 2009-02-03 2017-12-08 阿穆尼克斯运营公司 延伸重组多肽和包含该延伸重组多肽的组合物
US8703717B2 (en) 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
US8680050B2 (en) 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
US8716448B2 (en) 2009-02-03 2014-05-06 Amunix Operating Inc. Coagulation factor VII compositions and methods of making and using same
EP2440241B1 (en) 2009-06-08 2017-08-09 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
PT2440228T (pt) 2009-06-08 2018-12-24 Amunix Operating Inc Polipéptidos de regulação da glicose e métodos de preparação e utilização dos mesmos
WO2011028344A2 (en) 2009-08-25 2011-03-10 Amunix Operating Inc. Interleukin-1 receptor antagonist compositions and methods of making and using same
WO2011069164A2 (en) 2009-12-06 2011-06-09 Biogen Idec Ma Inc. Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
EP3508573A1 (en) 2010-07-09 2019-07-10 Bioverativ Therapeutics Inc. Systems for factor viii processing and methods thereof
EP2591006B1 (en) 2010-07-09 2019-04-24 Bioverativ Therapeutics Inc. Processable single chain molecules and polypeptides made using same
KR20230156435A (ko) 2010-07-09 2023-11-14 바이오버라티브 테라퓨틱스 인크. 인자 iｘ 폴리펩티드 및 이들의 사용 방법
PT2882450T (pt) 2012-07-11 2020-02-19 Bioverativ Therapeutics Inc Complexo de fator viii com xten e a proteína fator de von willebrand, e utilizações do mesmo
TW202003554A (zh) 2013-08-14 2020-01-16 美商百歐維拉提夫治療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
JP6909203B2 (ja) * 2015-08-03 2021-07-28 バイオベラティブ セラピューティクス インコーポレイテッド 第ｉｘ因子融合タンパク質及びそれらの製造方法及び使用方法

Also Published As

Publication number Publication date
WO2018144623A1 (en) 2018-08-09
EA201991768A1 (ru) 2020-01-22
KR20190112763A (ko) 2019-10-07
PH12019501765A1 (en) 2020-03-16
SG11201906788XA (en) 2019-08-27
MX2019009063A (es) 2019-10-21
TW201831521A (zh) 2018-09-01
EP3576762A1 (en) 2019-12-11
JP2020505424A (ja) 2020-02-20
CL2019002155A1 (es) 2020-02-21
AR110871A1 (es) 2019-05-08
IL268234A (en) 2019-09-26
AU2018215092A1 (en) 2019-08-29
BR112019015569A2 (pt) 2020-03-17
CN110831613A (zh) 2020-02-21
CA3051862A1 (en) 2018-08-09
US20210238259A1 (en) 2021-08-05
MA47416A (fr) 2019-12-11

Similar Documents

Publication Publication Date Title
CO2018002196A2 (es) Proteínas de fusión de factor ix y métodos para producirlas y utilizarlas
CO2020006900A2 (es) Medios y método para preparar vectores virales y usos de los mismos
MX2019007021A (es) Anticuerpos il-11ra.
MX2019007020A (es) Anticuerpos il-11.
MY198059A (en) Anti-ox40 antibodies and their uses
BR112017003414A2 (pt) composições compreendendo caseína e métodos para produzir as mesmas
PH12018502456A1 (en) Anti-cd04 antibodies and their uses
PH12016502142A1 (en) Anti-ptk7 antibody-drug conjugates
MX2018016038A (es) Compuestos y metodos para modular la funcion del acido ribonucleico (arn).
CL2019002605A1 (es) Formulaciones que contienen proteínas de unión pd-1 y métodos de fabricación de las mismas.
CL2019002251A1 (es) Anticuerpos contra triptasa, composiciones de estos y usos de estos.
BR112017025711A2 (pt) ?composições, processo para preparação de siloxanos modificados por poliéter e uso das composições inovadoras?
MX2018002061A (es) Soluciones de glicosidos de esteviol.
MX2021012973A (es) Sustituto de huevo y composiciones que comprenden el sustituto de huevo y metodos para producir el mismo.
MY193650A (en) Extracellular matrix compositions
DOP2016000220A (es) PROTEÍNAS DE FUSIÓN TATk-CDKL5, COMPOSICIONES, FORMULACIONES Y USO DE ESTAS.
MX2015014424A (es) Construcciones de proteinas mitocondriales y sus usos.
NZ742805A (en) Anti-cd22 antibody-maytansine conjugates and methods of use thereof
MX2017009180A (es) Biomateriales de nanocelulosa sintetizada bacterialmente y de fases múltiples, y método para producirlos.
CR20190389A (es) Proteínas de fusión del factor ix y procedimientos de preparación y utilización de las mismas
MX2017008612A (es) Películas envolventes con opacidad aumentada.
GEU20171919Y (en) Gel for electrotherapy
GT201600036S (es) Hermetico clip con color y diseño multiple
AU366513S (en) Electrode Holder